Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Real-time Estimate Cboe BZX
Other stock markets
 12:22:17 2024-06-11 pm EDT 		5-day change 1st Jan Change
6.445 USD -0.85% Intraday chart for Annovis Bio, Inc. -2.42% -65.51%
May. 10 Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
GL
ANNOVIS BIO INC. SCHEDULES INVESTOR WEBCAST
AQ
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
GL
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
AQ
Annovis Announces New Publication in a Peer-Reviewed Journal
GL
Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
BU
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
BU
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
GL
Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
GL
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
AQ
Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease
CI
Annovis Bio : Regulation FD Presentation - Form 8-K
PU
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
GL
Annovis Bio, Inc. Announces Henry Hagopian No Longer Serving as the Chief Financial Officer
CI
Annovis Bio, Inc. Announces Executive Changes
CI
Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT
Top Midday Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. News Annovis Bio, Inc.